Consortium

TACT consortium comprises six academic and three industrial beneficiary institutions located in five different countries
  • University of Strasbourg (UNISTRA – coordinator) is one of the largest universities in France, with nearly 50 800 students (20% of whom being international students) and over 2 645 teachers-researchers.With five Nobel laureates in activity, UNISTRA is one of the best university in the world for chemistry in various ranking tables.
  • Queen’s University Belfast (QUB) is ranked in the top 1% of universities in the world (QS World University Rankings, 2018) and is a member of the Russell group – a group of 24 leading UK research-intensive universities.
  • Wageningen University & Research (WUR) has a staff of 6,500 and 10,000 students from over 100 countries and is ranked 64 in Times Higher Education World University Rankings 2018 and ranked 36 for Life & Agriculture Sciences in Academic Ranking of World Universities 2016.
  • University College London (UCL) has been identified by the ‘UK Research Excellence Framework’ as the top university in the UK for research strength and is consistently placed in the global top 20 across a wide range of university rankings (currently joint 7th in the QS World University Rankings).
  • The National Center for Scientific Research (CNRS) is the principal funding organization for fundamental research in France and employs about 32000 scientists and technical and administrative research personnel in universities and specialized CNRS research centers in France.
  • Technical University of Munich (TUM) is one of Europe’s leading universities, with around 550 professors, 41 000 students, and 10 000 academic and non-academic staff.and has gained recognition as a German « Excellence University ».
  • Almac Discovery (AD) is a biopharmaceutical company focused on the discovery and development of innovative targeted approaches for the treatment of cancer and other diseases, with a strong small molecule and protein-based oncology pipeline and a particular focus on ubiquitin specific proteases and Protein-Drug Conjugates.
  • Heidelberg Pharma (HDP) is a biopharmaceutical company focused on the development of targeted toxin delivery for cancer treatment. HDP has a broad experience in conjugation of toxins to antibodies and also provides pre-clinical services, focusing on lead optimization and pre-clinical drug profiling.
  • SpiroChem AG (SPC) is the world-leading chemical company on the concept of bioisosterism, possessing a unique repertoire of molecular fragments designed to help medicinal chemists by accelerating drug discovery and lead optimization programmes in the Life Science sector.